A Phase 2 interventional study of CK-1827452 and CK-1827452 in Heart Failure, sponsored by Cytokinetics. Completed at 17 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-14.
Sponsored by Cytokinetics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing omecamtiv mecarbil in Heart Failure — 1 open to participants now, 1 under way, 1 of them phase 3. omecamtiv mecarbil · Heart Failure.
Among the 14 studies testing omecamtiv mecarbil in Heart Failure, this one is the 8th largest by enrollment, is the only one that started in 2007, is one of 7 in phase 2, and was the 1st registered.
6,332 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
Browse Heart Failure studies →1 of the 14 studies testing omecamtiv mecarbil in Heart Failure is open now, in 10 countries. Recruiting first, the newest first:
Cytokinetics · Sites in United States, Canada, China and 7 more countries
Ages 18–85
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2007.
This study's enrollment of 45 is below the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 48 across the 14 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 14 have an industry lead sponsor. The 1 most frequent:
Cytokinetics is the lead sponsor of 41 studies on the registry; 3 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 7 (64%) have results posted.
15 studies in Heart Failure by Cytokinetics: 2 open now, 2 under way, 1 of them phase 3. Of 11 finished, 8 (73%) have results posted.
Among the 15 studies in Heart Failure by Cytokinetics, this one is the 9th largest by enrollment, is the only one that started in 2007, is one of 8 in phase 2, and was the 1st registered.
Cytokinetics’s Heart Failure studies by the year they started, since 2005.
1 of the studies testing omecamtiv mecarbil in Heart Failure that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing omecamtiv mecarbil in Heart Failure, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Cytokinetics’s 15 in Heart Failure:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the safety, tolerability, and pharmacodynamics of CK-1827452 infusion in patients with stable heart failure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient is considered to be in suitable health in the opinion of the investigator, as determined by:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
Drug: CK-1827452 · Drug: Placebo
4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
Drug: CK-1827452 · Drug: Placebo
4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
Drug: Placebo · Drug: CK-1827452
4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
Drug: CK-1827452 · Drug: Placebo
2 treatment periods with a 72 hour infusion. The 2 treatment periods are randomly assigned and consist of 1 dose level of CK-1827452 (with dose de-escalation possible depending on tolerability) and 1 placebo treatment. Treatment period 2 occurs at least 7 days after the conclusion of period 1.
Drug: CK-1827452 · Drug: Placebo
IV infusion for 1 hour at 0.125 mg/kg/h followed by 1 hour at 0.0625 mg/kg/h
IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h
IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h
IV infusion for 1 hour at 0.75 mg/kg/h followed by 1 hour at 0.375 mg/kg/h
IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h
IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h followed by 22 hours at 0.025 mg/kg/h
IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h followed by 22 hours at 0.05 mg/kg/h
IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h followed by 22 hours at 0.1 mg/kg/h
IV infusion for 2 hours
IV infusion for 24 hours
IV infusion for 1 hour at 1.0 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h
IV infusion for 72 hours
IV infusion for 1 hour at 0.75 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h
IV infusion for 1 hour at 0.25 mg/kg/h followed by 23 hours at 0.025 mg/kg/h
IV infusion for 1 hour at 0.5 mg/kg/h followed by 23 hours at 0.05 mg/kg/h
IV infusion for 1 hour at 1.0 mg/kg/h followed by 23 hours at 0.1 mg/kg/h
Change From Baseline of Systolic Ejection Time at Various CK-1827452 Plasma Concentrations
Pooled analysis of the echocardiographic measure systolic ejection time from echocardiograms taken at all timepoints. The systolic ejection time is the period during which the aortic valve is open and blood is flowing across the valve. Echocardiograms from cohorts 1,2,3,4 and 5 (564 echocardiograms) were binned into either placebo group or 1 of 6 groups based on plasma concentration of CK-1827452.
Time frame: 4 days
Change From Baseline of Fractional Shortening at Various CK-1827452 Plasma Concentrations
Pooled analysis of the echocardiographic measure fractional shortening from echocardiograms taken at all timepoints. Fractional shortening is the percentage of change from baseline in the left ventricular cavity dimension with systole. Echocardiograms from cohorts 1,2,3,4 and 5 (564 echocardiograms) were binned into either placebo group or 1 of 6 groups based on plasma concentration of CK-1827452.
Time frame: 4 days
CK-1827452 Maximum Observed Plasma Concentration (Cmax)
Determined by evaluation of plasma concentrations from blood samples collected prior to dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24 and 48 hours after initiation of study drug infusion
Time frame: 2 days
CK-1827452 Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Plasma Concentration (AUClast)
Determined by evaluation of plasma concentrations from blood samples collected prior to dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24 and 48 hours after initiation of study drug infusion
Time frame: 2 days
The recruitment period was from April 2007 to January 2009.
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 |
|---|---|---|---|---|---|
| Started | 8 | 9 | 10 | 8 | 10 |
| Completed | 8 | 8 | 8 | 8 | 8 |
| Not completed | 0 | 1 | 2 | 0 | 2 |
Pooled analysis of the echocardiographic measure systolic ejection time from echocardiograms taken at all timepoints. The systolic ejection time is the period during which the aortic valve is open and blood is flowing across the valve. Echocardiograms from cohorts 1,2,3,4 and 5 (564 echocardiograms) were binned into either placebo group or 1 of 6 groups based on plasma concentration of CK-1827452.
| msec | >0-100 ng/mL | >100-200 ng/mL | >200-300 ng/mL | >300-400 ng/mL | >400-500 ng/mL | >500 ng/mL |
|---|---|---|---|---|---|---|
| # of Echocardiographic Observations (no units) | 84 ± 0 | 62 ± 0 | 42 ± 0 | 24 ± 0 | 20 ± 0 | 46 ± 0 |
| Ejection Fraction msec Change from Baseline | 1 ± 4 | 18 ± 4 | 47 ± 5 | 58 ± 6 | 59 ± 6 | 80 ± 5 |
Pooled analysis of the echocardiographic measure fractional shortening from echocardiograms taken at all timepoints. Fractional shortening is the percentage of change from baseline in the left ventricular cavity dimension with systole. Echocardiograms from cohorts 1,2,3,4 and 5 (564 echocardiograms) were binned into either placebo group or 1 of 6 groups based on plasma concentration of CK-1827452.
| Percentage of change | >0-100 ng/mL | >100-200 ng/mL | >200-300 ng/mL | >300-400 ng/mL | >400-500 ng/mL | >500 ng/mL |
|---|---|---|---|---|---|---|
| # of Echocardiographic Observations (no units) | 81 ± 0 | 56 ± 0 | 37 ± 0 | 23 ± 0 | 17 ± 0 | 44 ± 0 |
| Fractional Shortening Percent Change from Baseline | 1 ± 1 | 1 ± 1 | 3 ± 1 | 3 ± 1 | 2 ± 1 | 5 ± 1 |
Determined by evaluation of plasma concentrations from blood samples collected prior to dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24 and 48 hours after initiation of study drug infusion
| nanogram/milliliter | Cohort 1/2: 0.125 mg/kg/h + 0.0625 mg/kg/h | Cohort 1/2: 0.25 mg/kg/h + 0.125 mg/kg/h | Cohort 1/2: 0.5 mg/kg/h + 0.25 mg/kg/h | Cohort 1/2: 0.75 mg/kg/h + 0.375 mg/kg/h | Cohort 1/2: 1.0 mg/kg/h + 0.5 mg/kg/h | Cohort 3: 0.25 mg/kg/h + 0.025 mg/kg/h | Cohort 3: 0.5 mg/kg/h + 0.05 mg/kg/h | Cohort 3: 1.0 mg/kg/h + 0.1 mg/kg/h | Cohort 4: 0.25 mg.kg.h + 0.125 mg/kg/h + 0.025 mg/kg/h | Cohort 4: 0.5 mg/kg/h + 0.25 mg/kg/h + 0.05 mg/kg/h | Cohort 4: 1.0 mg/kg/h + 0.5 mg/kg/h + 0.1 mg/kg/h | Cohort 5: 1.0 mg/kg/h + 0.5 mg/kg/h + 0.1 mg/kg/h | Cohort 5: 0.75 mg/kg/h + 0.375 mg/kg/h + 0.075 mg/kg/h |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CK-1827452 Maximum Observed Plasma Concentration (Cmax) | 96.1 ± 27.8 | 195.0 ± 69.4 | 347.1 ± 108.6 | 558.1 ± 156.5 | 635.9 ± 158.0 | 165.3 ± 51.4 | 279.9 ± 55.0 | 633.0 ± 161.5 | 177.9 ± 103.4 | 403.3 ± 226.2 | 681.4 ± 159.2 | 884.5 ± 316.2 | 726.9 ± 62.4 |
Determined by evaluation of plasma concentrations from blood samples collected prior to dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24 and 48 hours after initiation of study drug infusion
| hour x nanogram/milliliter | Cohort 1/2: 0.125 mg/kg/h + 0.0625 mg/kg/h | Cohort 1/2: 0.25 mg/kg/h + 0.125 mg/kg/h | Cohort 1/2: 0.5 mg/kg/h + 0.25 mg/kg/h | Cohort 1/2: 0.75 mg/kg/h + 0.375 mg/kg/h | Cohort 1/2: 1.0 mg/kg/h + 0.5 mg/kg/h | Cohort 3: 0.25 mg/kg/h + 0.025 mg/kg/h | Cohort 3: 0.5 mg/kg/h + 0.05 mg/kg/h | Cohort 3: 1.0 mg/kg/h + 0.1 mg/kg/h | Cohort 4: 0.25 mg.kg.h + 0.125 mg/kg/h + 0.025 mg/kg/h | Cohort 4: 0.5 mg/kg/h + 0.25 mg/kg/h + 0.05 mg/kg/h | Cohort 4: 1.0 mg/kg/h + 0.5 mg/kg/h + 0.1 mg/kg/h | Cohort 5: 1.0 mg/kg/h + 0.5 mg/kg/h + 0.1 mg/kg/h | Cohort 5: 0.75 mg/kg/h + 0.375 mg/kg/h + 0.075 mg/kg/h |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CK-1827452 Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Plasma Concentration (AUClast) | 1102.2 ± 257.6 | 2314.3 ± 640.9 | 4252.7 ± 1296.7 | 6060.7 ± 1741.7 | 8495.7 ± 3178.3 | 3982.7 ± 1070.2 | 8120.5 ± 2268.9 | 18450.7 ± 4747.8 | 4399.0 ± 1483.2 | 10624.8 ± 5168.3 | 19394.3 ± 4230.6 | 59044.6 ± 17693.2 | 43605.5 ± 3551.0 |
Collected over 5 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/41 (0%) | 8/41 (19.5%) |
| Cohorts 1 and/or 2, Loading Dose of 0.125 mg/kg/hr | — | 0/8 (0%) | 1/8 (12.5%) |
| Cohorts 1 and/or 2, Loading Dose of 0.25 mg/kg/hr | — | 0/9 (0%) | 0/9 (0%) |
| Cohorts 1 and/or 2, Loading Dose of 0.5 mg/kg/hr | — | 0/16 (0%) | 1/16 (6.3%) |
| Cohorts 1 and/or 2, Loading Dose of 1.0 mg/kg/hr | — | 0/6 (0%) | 4/6 (66.7%) |
| Cohorts 1 and/or 2, Loading Dose of 0.75 mg/kg/hr | — | 0/8 (0%) | 0/8 (0%) |
| Cohort 2, Loading Dose of 2.2 mg/kg/hr | — | 1/1 (100%) | 1/1 (100%) |
| Cohorts 3 and 4, Loading Dose of 0.25 mg/kg/hr | — | 1/18 (5.6%) | 6/18 (33.3%) |
| Cohorts 3 and 4, Loading Dose of 0.5 mg/kg/hr | — | 1/18 (5.6%) | 4/18 (22.2%) |
| Cohorts 3 and 4, Loading Dose of 1.0 mg/kg/hr | — | 0/16 (0%) | 1/16 (6.3%) |
| Cohort 5, Loading Dose of 0.75 mg/kg/hr | — | 0/2 (0%) | 1/2 (50%) |
| Cohort 5, Loading Dose of 1.0 mg/kg/hr | — | 0/8 (0%) | 2/8 (25%) |
| Event | Placebo | Cohorts 1 and/or 2, Loading Dose of 0.125 mg/kg/hr | Cohorts 1 and/or 2, Loading Dose of 0.25 mg/kg/hr | Cohorts 1 and/or 2, Loading Dose of 0.5 mg/kg/hr | Cohorts 1 and/or 2, Loading Dose of 1.0 mg/kg/hr | Cohorts 1 and/or 2, Loading Dose of 0.75 mg/kg/hr | Cohort 2, Loading Dose of 2.2 mg/kg/hr | Cohorts 3 and 4, Loading Dose of 0.25 mg/kg/hr | Cohorts 3 and 4, Loading Dose of 0.5 mg/kg/hr | Cohorts 3 and 4, Loading Dose of 1.0 mg/kg/hr | Cohort 5, Loading Dose of 0.75 mg/kg/hr | Cohort 5, Loading Dose of 1.0 mg/kg/hr |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non ST elevation MI in patient with drug overdoseCardiac disorders | 0/41 | 0/8 | 0/9 | 0/16 | 0/6 | 0/8 | 1/1 | 0/18 | 0/18 | 0/16 | 0/2 | 0/8 |
| Septicemia in setting of diabetic foot ulcerMetabolism and nutrition disorders | 0/41 | 0/8 | 0/9 | 0/16 | 0/6 | 0/8 | 0/1 | 1/18 | 0/18 | 0/16 | 0/2 | 0/8 |
| PneumoniaInfections and infestations | 0/41 | 0/8 | 0/9 | 0/16 | 0/6 | 0/8 | 0/1 | 0/18 | 1/18 | 0/16 | 0/2 | 0/8 |
| Event | Placebo | Cohorts 1 and/or 2, Loading Dose of 0.125 mg/kg/hr | Cohorts 1 and/or 2, Loading Dose of 0.25 mg/kg/hr | Cohorts 1 and/or 2, Loading Dose of 0.5 mg/kg/hr | Cohorts 1 and/or 2, Loading Dose of 1.0 mg/kg/hr | Cohorts 1 and/or 2, Loading Dose of 0.75 mg/kg/hr | Cohort 2, Loading Dose of 2.2 mg/kg/hr | Cohorts 3 and 4, Loading Dose of 0.25 mg/kg/hr | Cohorts 3 and 4, Loading Dose of 0.5 mg/kg/hr | Cohorts 3 and 4, Loading Dose of 1.0 mg/kg/hr | Cohort 5, Loading Dose of 0.75 mg/kg/hr | Cohort 5, Loading Dose of 1.0 mg/kg/hr |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Troponin increasedInvestigations | 0/41 | 0/8 | 0/9 | 0/16 | 0/6 | 0/8 | 1/1 | 0/18 | 0/18 | 0/16 | 0/2 | 2/8 |
| Orthostatic hypotensionVascular disorders | 2/41 | 0/8 | 0/9 | 0/16 | 1/6 | 0/8 | 0/1 | 1/18 | 1/18 | 0/16 | 1/2 | 0/8 |
| Dizziness posturalNervous system disorders | 0/41 | 0/8 | 0/9 | 0/16 | 1/6 | 0/8 | 0/1 | 1/18 | 1/18 | 0/16 | 0/2 | 0/8 |
| HypotensionVascular disorders | 0/41 | 0/8 | 0/9 | 0/16 | 1/6 | 0/8 | 0/1 | 1/18 | 0/18 | 0/16 | 0/2 | 0/8 |
| Sinus bradycardiaCardiac disorders | 0/41 | 0/8 | 0/9 | 0/16 | 1/6 | 0/8 | 0/1 | 0/18 | 0/18 | 0/16 | 0/2 | 1/8 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 1/41 | 1/8 | 0/9 | 0/16 | 0/6 | 0/8 | 0/1 | 0/18 | 0/18 | 0/16 | 0/2 | 0/8 |
| SomnolenceNervous system disorders | 1/41 | 0/8 | 0/9 | 0/16 | 0/6 | 0/8 | 0/1 | 0/18 | 1/18 | 1/16 | 0/2 | 0/8 |
| Urinary tract infectionInfections and infestations | 1/41 | 0/8 | 0/9 | 1/16 | 0/6 | 0/8 | 0/1 | 0/18 | 0/18 | 0/16 | 0/2 | 0/8 |
| ConstipationGastrointestinal disorders | 2/41 | 0/8 | 0/9 | 0/16 | 0/6 | 0/8 | 0/1 | 1/18 | 0/18 | 0/16 | 0/2 | 0/8 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/41 | 0/8 | 0/9 | 0/16 | 0/6 | 0/8 | 0/1 | 1/18 | 0/18 | 0/16 | 0/2 | 0/8 |
| Age, Categorical(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 7 | 6 | 5 | 7 | 30 |
| >=65 years | 3 | 2 | 4 | 3 | 3 | 15 |
| Age, Continuous(years) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Total |
|---|---|---|---|---|---|---|
| Mean | 59.0 ± 11.9 | 56.0 ± 14.3 | 62.0 ± 8.2 | 52.6 ± 18.0 | 57.0 ± 14.0 | 57.5 ± 13.2 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 1 | 0 | 3 | 2 | 6 |
| Male | 8 | 8 | 10 | 5 | 8 | 39 |
| Region of Enrollment(participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Total |
|---|---|---|---|---|---|---|
| United States | 0 | 0 | 0 | 1 | 2 | 3 |
| Georgia | 0 | 0 | 0 | 0 | 2 | 2 |
| Russian Federation | 0 | 4 | 4 | 2 | 1 | 11 |
| United Kingdom | 8 | 5 | 6 | 5 | 5 | 29 |
The record gives a start of Apr 2007, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omecamtiv mecarbil